Reactions 1680, p39 - 2 Dec 2017 Atypia: 5 case reports In a retrospective study, five women, aged 29 52 years, were described who developed cervical atypia during treatment with cyclophosphamide and busulfan (two women), fludarabine, busulfan and cyclophosphamide (two women) and fludarabine, cytarabine, busulfan and cyclophosphamide (one woman) [not all dosages and routes stated]. Additionally, all the women received mesna. The women underwent haematopoietic stem cell transplantation (HSCT). They received myeloablative conditioning (MAC) therapy (two women) and reduced intensity-conditioning (RIC) therapy (three women). The MAC therapy was consisted of IV busulfan 3.2 mg/kg/day for four days and cyclophosphamide 60 mg/kg/day for two days. The RIC was consisted of IV busulfan 3.2 mg/kg/day for two days, fludarabine 30 mg/m /day for five days and cyclophosphamide 50 mg/kg/day for one day in two women and in the remaining woman, the RIC was consisted of fludarabine, cytarabine, busulfan and cyclophosphamide. All the women received prophylactic mesna. After 34-183 days of HSCT, all the women developed therapy-related atypia. One out of these five women underwent cervical biopsy, which suggestive of therapy-related atypia. A pap smears tests findings were consistent with the diagnosis of atypical squamous cells of undetermined significance (ASC-US) in two women. The therapy-related atypia was transient in nature. Twenty to twenty nine months after HSCT, the pap smears tests showed no atypia in three women. Author comment: "In summary, therapy-related atypia is extremely common during the acute phase after HSCT. The atypical cytology is probably associated with conditioning chemotherapy, particularly busulfan-containing regimens." Yu S-C, et al. Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. Biology of Blood and Marrow Transplantation 23: 1367-1373, No. 8, Aug 2017. Available from: URL: http://doi.org/10.1016/j.bbmt.2017.04.022 - Taiwan 803285536 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera